Skip to main content

Table 5 Summary of adverse drug reactions

From: An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

 

Patients (N = 633)a

Patients with ADRs, n (%)

116 (18.3)

ADRs in > 2% of patients, n (%)

 Eyelid ptosis

34 (5.4)

 Neck pain

18 (2.8)

 Musculoskeletal stiffness

17 (2.7)

ADR intensity, n (%)b

 Mild

45 (7.3)

 Moderate

47 (7.4)

 Severe

24 (3.8)

ADR relationship, n (%)b,c

 Possible

17 (2.7)

 Probable

31 (4.9)

 Definite

61 (9.6)

Serious ADRs, n (%)

8 (1.3)

  1. ADR = adverse drug reaction
  2. aPercentages are based on total number of patients
  3. bPatients who experienced more than 1 ADR were counted at the maximum intensity or highest causal relationship
  4. cCausal relationship as assessed by the investigator